{"id":"7d364a4b3ffe","type":"article","url":"https://hartvaat.nl/2026/02/09/coronaire-atherosclerose-bij-kankerpatienten-en-overlevenden-aha-statement/","title":"Coronaire atherosclerose bij kankerpatiënten en -overlevenden (AHA-statement)","title_en":"Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association","category":"preventie","category_label":"Preventie","professions":["cardioloog","internist"],"tags":["acuut-coronair-syndroom","acuut-hartfalen","lipide-aferese"],"journal":"Circulation","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001391","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/CIR.0000000000001391","authors":["Lili Zhang"],"significance":8,"published":"2026-02-09","source_date":"2026-02-09","image":"","kennis":["https://hartvaat.nl/kennis/cardiometabool/obesitas-en-hart/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This AHA scientific statement addressed the emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors, overlapping pathophysiology, and the cardiovascular toxicity of cancer therapies.","created":"2026-07-03T10:25:24Z","updated":"2026-07-03T13:24:49Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Er is een toenemende convergentie tussen atherosclerotische hart- en vaatziekten en kanker door gedeelde risicofactoren en overlappende pathofysiologische mechanismen. Dit AHA-wetenschappelijk statement bespreekt de implicaties voor klinische zorg.","abstract_original":"There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments—including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)—that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis"}